MiMedx Group Statistics
Total Valuation
MiMedx Group has a market cap or net worth of $753.06 million. The enterprise value is $583.43 million.
Important Dates
The last earnings date was Wednesday, February 25, 2026, after market close.
| Earnings Date | Feb 25, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
MiMedx Group has 148.09 million shares outstanding. The number of shares has increased by 0.45% in one year.
| Current Share Class | 148.10M |
| Shares Outstanding | 148.09M |
| Shares Change (YoY) | +0.45% |
| Shares Change (QoQ) | +0.32% |
| Owned by Insiders (%) | 1.78% |
| Owned by Institutions (%) | 53.41% |
| Float | 117.27M |
Valuation Ratios
The trailing PE ratio is 15.66 and the forward PE ratio is 41.75.
| PE Ratio | 15.66 |
| Forward PE | 41.75 |
| PS Ratio | 1.75 |
| Forward PS | 1.79 |
| PB Ratio | 3.05 |
| P/TBV Ratio | 3.28 |
| P/FCF Ratio | 10.03 |
| P/OCF Ratio | 9.89 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 7.41, with an EV/FCF ratio of 8.00.
| EV / Earnings | 12.01 |
| EV / Sales | 1.39 |
| EV / EBITDA | 7.41 |
| EV / EBIT | 9.13 |
| EV / FCF | 8.00 |
Financial Position
The company has a current ratio of 4.32, with a Debt / Equity ratio of 0.07.
| Current Ratio | 4.32 |
| Quick Ratio | 3.76 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | 0.23 |
| Debt / FCF | 0.25 |
| Interest Coverage | -21.78 |
Financial Efficiency
Return on equity (ROE) is 21.61% and return on invested capital (ROIC) is 41.92%.
| Return on Equity (ROE) | 21.61% |
| Return on Assets (ROA) | 13.17% |
| Return on Invested Capital (ROIC) | 41.92% |
| Return on Capital Employed (ROCE) | 22.95% |
| Weighted Average Cost of Capital (WACC) | 12.40% |
| Revenue Per Employee | $500,155 |
| Profits Per Employee | $58,038 |
| Employee Count | 837 |
| Asset Turnover | 1.38 |
| Inventory Turnover | 2.97 |
Taxes
In the past 12 months, MiMedx Group has paid $17.68 million in taxes.
| Income Tax | 17.68M |
| Effective Tax Rate | 26.69% |
Stock Price Statistics
The stock price has decreased by -37.00% in the last 52 weeks. The beta is 1.59, so MiMedx Group's price volatility has been higher than the market average.
| Beta (5Y) | 1.59 |
| 52-Week Price Change | -37.00% |
| 50-Day Moving Average | 5.83 |
| 200-Day Moving Average | 6.60 |
| Relative Strength Index (RSI) | 35.15 |
| Average Volume (20 Days) | 866,853 |
Short Selling Information
The latest short interest is 7.14 million, so 4.82% of the outstanding shares have been sold short.
| Short Interest | 7.14M |
| Short Previous Month | 6.34M |
| Short % of Shares Out | 4.82% |
| Short % of Float | 6.09% |
| Short Ratio (days to cover) | 7.02 |
Income Statement
In the last 12 months, MiMedx Group had revenue of $418.63 million and earned $48.58 million in profits. Earnings per share was $0.32.
| Revenue | 418.63M |
| Gross Profit | 345.62M |
| Operating Income | 63.89M |
| Pretax Income | 66.26M |
| Net Income | 48.58M |
| EBITDA | 78.77M |
| EBIT | 63.89M |
| Earnings Per Share (EPS) | $0.32 |
Full Income StatementBalance Sheet
The company has $166.12 million in cash and $17.97 million in debt, with a net cash position of $148.15 million or $1.00 per share.
| Cash & Cash Equivalents | 166.12M |
| Total Debt | 17.97M |
| Net Cash | 148.15M |
| Net Cash Per Share | $1.00 |
| Equity (Book Value) | 256.55M |
| Book Value Per Share | 1.73 |
| Working Capital | 213.21M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $74.00 million and capital expenditures -$1.03 million, giving a free cash flow of $72.97 million.
| Operating Cash Flow | 74.00M |
| Capital Expenditures | -1.03M |
| Free Cash Flow | 72.97M |
| FCF Per Share | $0.49 |
Full Cash Flow StatementMargins
Gross margin is 82.56%, with operating and profit margins of 15.26% and 11.60%.
| Gross Margin | 82.56% |
| Operating Margin | 15.26% |
| Pretax Margin | 15.83% |
| Profit Margin | 11.60% |
| EBITDA Margin | 18.82% |
| EBIT Margin | 15.26% |
| FCF Margin | 17.43% |
Dividends & Yields
MiMedx Group does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.45% |
| Shareholder Yield | -0.45% |
| Earnings Yield | 6.64% |
| FCF Yield | 9.97% |
Analyst Forecast
The average price target for MiMedx Group is $10.00, which is 96.66% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $10.00 |
| Price Target Difference | 96.66% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | 14.60% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 5 |
